Climate footprint of industry-sponsored clinical research: an analysis of a phase-1 randomised clinical study and discussion of opportunities to reduce its impact
Objective This study aims to calculate the global warming potential, in carbon dioxide (CO2) equivalent emissions, from all in-scope activities involved in a phase-1 clinical study.Design Retrospective analysis.Data source Internal data held by Janssen Pharmaceuticals.Studies included Janssen-sponso...
Main Authors: | Michael Collins, Thomas Costelloe, Jason Keith LaRoche, Rodrigo Alvarenga, Wouter De Soete, Jeremy Faludi, Kristel Rens |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-01-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/14/1/e077129.full |
Similar Items
-
Carbon footprint of industry-sponsored late-stage clinical trials
by: Michael Collins, et al.
Published: (2023-08-01) -
The Economic Contribution of Industry-Sponsored Pharmaceutical Clinical Trials
by: Dat T Tran, et al.
Published: (2018-01-01) -
Diversity in Oncology Clinical Trials: Current Landscape for Industry-Sponsored Clinical Trials in Asia
by: Dany Habr, et al.
Published: (2023-12-01) -
Sponsors
by: Swiss Chemical Society
Published: (2005-07-01) -
Sponsor page
Published: (2022-09-01)